Art Bioscience
Israel - RehovotBiotechnology
Focus: Art Bioscience is a publicly traded Israeli biotech specializing in gene therapy for Duchenne muscular dystrophy (DMD), operating from Rehovot with a highly focused pipeline.
Profile data last refreshed 5h ago · AI intelligence enriched 3d ago
Funding Stage
PUBLIC
Open Jobs
3
Should You Work at Art Bioscience?
AI assessmentArt Bioscience represents a high-risk, high-reward opportunity for gene therapy specialists willing to accept limited near-term hiring and long development timelines.
Why Work Here
- Focused gene therapy platform targeting rare disease (DMD) with significant unmet medical need and potential for premium pricing
- Public company status provides liquidity and access to capital markets for R&D funding
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Art Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.